Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market, Says Frost & Sullivan

Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market, Says Frost & Sullivan PR Newswire LONDON, Dec. 12, 2012 - Participants need to focus on product customisation, ease-of-use and reliability LONDON, Dec. 12, 2012 /PRNewswire/ -- Cardiovascular disease (CVD) is the main cause of death in the EU, killing over 2 million people annually and costing the economy nearly €192 billion. Prevention, through constant monitoring of heart health, is seen as the best way to tackle this high death rate. The most accurate way of monitoring heart health is through cardiac marker testing. Regular monitoring of cardiac health through brain natriuretic peptide (BNP) testing is being practiced across Europe, thereby boosting the cardiac marker testing market. New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Analysis of European Cardiac Biomarkers Diagnostics Market, finds that the market earned revenues of about $607.9 million in 2011 and estimates this to double to reach $1,216.0 million in 2018. The research covers acute myocardial infarction (AMI) and congestive heart failure (CHF) biomarkers diagnostics. The increasing role of cardiac markers in patient triaging is further boosting market expansion. Effective implementation of cardiac markers can enable decreased bed occupancy, reduced hospital costs and physician time.